Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (181-190 of 241) with videos related to

Pageof 25
Sort By:
The Lancet. Infectious Diseases|April 17, 2015
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Dianne Carey, Rebekah Puls, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 18, 2016
Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 TrialAlan Winston, Wolfgang Stöhr, Andrea Antinori, et al.
Translational Psychiatry|June 6, 2023
Biomarkers of central and peripheral inflammation mediate the association between HIV and depressive symptomsArish Mudra Rakshasa-Loots, Nicholas Bakewell, David J Sharp, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous MeningitisSam Nightingale, Tran Thi Hong Chau, Martin Fisher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2016
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Hans Rolf Jäger, et al.
AIDS (London, England)|February 26, 2021
Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individualsDavide De Francesco, Caroline A Sabin, Alan Winston, et al.
AIDS (London, England)|June 15, 2021
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-seriesTerrence Y-H Chan, Valentina De Zan, Alistair Gregg, et al.
International Journal of STD & AIDS|April 20, 2019
Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individualsDavide De Francesco, Alan Winston, Jonathan Underwood, et al.
Plos Pathogens|October 4, 2022
Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccinesTamara Elliott, Hannah M Cheeseman, Abbey B Evans, et al.
Open Forum Infectious Diseases|July 7, 2017
High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal FluidThijs Booiman, Ferdinand W Wit, Irma Maurer, et al.
Pageof 25

Showing results (181-190 of 241) with videos related to

Sort By:
Pageof 25
The Lancet. Infectious Diseases|April 17, 2015
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Dianne Carey, Rebekah Puls, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 18, 2016
Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 TrialAlan Winston, Wolfgang Stöhr, Andrea Antinori, et al.
Translational Psychiatry|June 6, 2023
Biomarkers of central and peripheral inflammation mediate the association between HIV and depressive symptomsArish Mudra Rakshasa-Loots, Nicholas Bakewell, David J Sharp, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous MeningitisSam Nightingale, Tran Thi Hong Chau, Martin Fisher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2016
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Hans Rolf Jäger, et al.
AIDS (London, England)|February 26, 2021
Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individualsDavide De Francesco, Caroline A Sabin, Alan Winston, et al.
AIDS (London, England)|June 15, 2021
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-seriesTerrence Y-H Chan, Valentina De Zan, Alistair Gregg, et al.
International Journal of STD & AIDS|April 20, 2019
Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individualsDavide De Francesco, Alan Winston, Jonathan Underwood, et al.
Plos Pathogens|October 4, 2022
Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccinesTamara Elliott, Hannah M Cheeseman, Abbey B Evans, et al.
Open Forum Infectious Diseases|July 7, 2017
High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal FluidThijs Booiman, Ferdinand W Wit, Irma Maurer, et al.
Pageof 25